Introduction. We looked for novel binding sites for the human prorenin 'decoy peptide' sometimes called 'handle region peptide' on human endothelial cells. Method. The biotinylated peptide biotin-Acp-RIFLKRMPSIR (B-PR), an unlabelled peptide PR1 (RIFLKRMPSIR) and a scrambled peptide scPR1 (SRRMIFPIKLR) were synthesized. B-PR was added to human umbilical cord endothelial cells (HUVECs) maintained in serum-free medium, with or without excess unlabelled peptide or 'scrambled' peptide as blocker. Biotin-labelled HUVEC proteins were extracted, the amount of bound tracer was measured, and the identity of the binding proteins was analysed by sodium-dodecyl-sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Results. Biotinylated peptide bound to the HUVEC proteins with a major labelled band at 68,600 + 1503 kDa (mean + SEM, n=5 runs). Unlabelled peptide and scrambled peptide equally displaced the labelled peptide, indicating that the binding was non-specific for amino acid sequence. LC-MS/MS showed that binding was mainly to cytoskeletal proteins. Conclusion. The binding of the human prorenin peptide R 10 IFLKRMPSIR 20 to HUVEC proteins is not specific for amino acid sequence and probably involves a general peptide/protein uptake mechanism. We could not detect a specific prorenin propart binding site in these cells.
Introduction
A peptide from the rat prorenin propart was reported to block diabetic renal damage in rats 1 and act as a ligand for the renin/prorenin receptor, 2 although more recently some laboratories were unable to show any biological action of the prorenin 'decoy' peptide. [3] [4] [5] Prorenin is the precursor of enzymatically active renin, 6 human prorenin comprises over 50% of total circulating renin, 7 and its circulating concentration is increased in patients with diabetic vascular disease. 8 Rats with high circulating levels of prorenin expressed from the liver show vascular damage. 9 Following the original reports, it seemed an attra-ctive hypothesis that binding sites for the human prorenin propart might exist on endothelial cells and contribute to vascular disease. The renin/prorenin receptor described by Nguyen et al. 2 binds both prorenin and renin, and is therefore not specific for the prorenin sequence, so we did not assume that the hypothetical prorenin peptide binding site would be identical to this receptor. We designed a biotinylated peptide to use as a ligand, and tested its binding to cultured human endothelial cells as described below.
Methods

Peptides
A peptide corresponding to the human renin propart sequence 10-20 with a biotin label at the N-terminus, biotin-Acp-RIFLKRMPSIR (B-PR) was synthesized by GenScript Corp, NJ, to over 90% purity as shown by high-performance liquid chromatography (HPLC) and mass spectrometry (MS) data provided by the company. The B-PR was used as a tracer to label binding sites on human endothelial cells. The unlabelled peptide PR (RIFLKRMPSIR) and the scrambled peptide scPR (SRRMIFPIKLR) were also synthesized to over 90% purity and used as blockers for the labelled ligand. All peptides were dissolved in sterile phosphate buffered saline (PBS; 137.9 mmol/L NaCl, 10.1 mmol/L Na 2 HPO 4 , 1.76 mmol/L KH 2 PO4, 2.68 mmol/L KCl, pH 7.4) and used at the concentrations indicated.
Human endothelial cells
Human umbilical vein endothelial cells (HUVECs) (passage 2-6) from a tissue bank established in this Paper SAGE Publications 2010 Los Angeles, London, New Delhi and Singapore department were grown in complete medium (Medium 199 + 20% foetal calf serum (FCS), with sodium pyruvate (1 mmol/L), HEPES buffer (0.02 mol/L), penicillin (100 units/ml), streptomycin (1 mg/ml), and endothelial cell growth supplement (Calbiochem) at 5 µg/ml. The identity of the cells was confirmed by staining for von Willebrand factor and examination of cell morphology. The cells were plated into 12-well or 24-well culture plates and used at around 80% confluence. 48 hours before the start of the experiment, the cells were washed twice in serum-free endothelial cell (EC) medium without growth factors (Gibco/ Invitrogen EC medium cat. No 11111) and maintained in the EC medium, with one change of medium after 24 hours.
Binding experiments
HUVECs were washed three times in PBS, the plate was placed on ice and 1 ml B-PR was added, with or without at least a 20-fold excess of blocker PR or scrambled blocker scPR. The concentration of added B-PR varied from 10 -7 to 10 -4 M. Experimental wells were set up in triplicate. The cells were left on ice for 15 minutes, the peptides were removed, the cells rapidly washed with 1 ml cold PBS, and bound peptides were cross-linked to the HUVECs with 0.2 ml 5 mM SB3 (suberic acid bis(3-sulfo-N-hydroxysuccinimide ester) sodium salt) for 2 hours on ice. The cross-linking was terminated with 0.1 ml of 2 M Tris pH 7.5, and total HUVEC proteins extracted with 200 µl Cell-Lytic (Sigma) containing protease inhibitors (Sigma catalogue number 2714 at the recommended concentration). Extracts were spun for 2 minutes in an Epindorf centrifuge and the supernatants stored at -20 o C until used. Binding experiments were carried out three times independently.
Analysis of biotinylated HUVEC proteins
Sodium-dodecyl-sulphate gel electrophoresis
Samples of biotinylated HUVEC proteins were run on sodium-dodecyl-sulphate (SDS) polyacrylamide gels (10%), blotted on to nitrocellulose membrane, the blots were blocked with 1% bovine serum albumin BSA in PBS + 0.05% Tween 20 and biotinylated proteins detected with streptavidin/peroxidase (ultrasensitive polymer, Sigma catalogue number S2438) and chemiluminescent peroxidase substrate (SuperSignal West, catalogue number 34077 Pierce Chemical Company). For Western blotting, samples of endothelial cell extract from control wells without added B-PR were mixed with 1/3 volume of sample buffer (12.5mmol/L Tris/HCl pH 6.8, 10% SDS, 0.1% Bromophenol Blue, 5% glycerol, 0.25 M dithiothreitol), heated to 95 o C for 5 minutes, quenched on ice, centrifuged briefly and 3 µg of protein in the supernatant loaded on to 12% gels, run and blotted onto nitrocellulose membrane as before, with standard proteins as markers (BioRad 161-0318). Blots were blocked with 1% BSA and developed with antibody raised to an epitope on the soluble domain of the (pro)renin receptor 10 (a gift from Professor G Nguyen). Controls were also run on cell extracts expressing the prorenin receptor protein 10 .
Slot-blot for measurement of biotin binding to endothelial cell proteins
The method was a modification of the dot-blot method of Bolte et al. 11 Samples (20-50 µl) of biotinylated protein extracts containing 2 µg of protein were blotted on to nitrocellulose (Slotblot apparatus, BioRad) in duplicate. A standard was prepared of biotinylated ovalbumin with a known amount of biotin per milligram protein, and dilutions of this were blotted in triplicate on the same blot as the samples. The blot was blocked with BSA, developed with streptavidin/ peroxidase (Sigma) and a chemiluminescent peroxidase substrate (Pierce) and the density of each blot was measured (ImageMaster, Pharmacia, Sweden). The amount of biotin bound to the endothelial cell extracts was calculated from the biotinylated ovalbumin standard curve relating amount of biotinylated protein to blot density. The limit of detection was 2-5 pmol of biotin. Cell extracts without added B-PR did not give a signal. Results were calculated as picomoles of biotin per microgram of protein.
Protein was measured by the Peterson's modification of the Folin method. 12
Liquid chromatography coupled with mass spectrometry Analysis of proteins binding to the B-PR ligand was carried out by a modification of published methods, 13 in which the biotinylated ligand is cross-linked to the protein binding partner, the complex is isolated by affinity chromatography on avidin resin, and the identity of the binding partner examined using LC-MS/MS. Two separate samples of HUVECs were grown in five 75 ml flasks and labelled with B-PR (without the blocking peptide PR) as described above. All subsequent extractions were carried out with precautions to prevent contamination with extraneous protein. Briefly, 5 ml protein extract was equilibrated with 50 mM Tris/HCl pH 8.0 and incubated with 2 ml avidin resin (Promega) in the same buffer, overnight at 4 o C with gentle shaking. The resin was placed in a column and washed with 2 ml equilibration buffer, then the bound proteins eluted with 6 ml 10% acetic acid, and collected directly into a tube containing 0.6 ml 2 M Tris/HCl pH 7.5. The volume was reduced by filter centrifugation and the protein solution dialysed overnight against ultrapure water. One cell preparation was subjected to LC-MS/MS analysis after the affinity chromatography, the other was run on SDS-PAGE, stained with Coomassie Blue and stained bands were excised and then analysed. LC-MS/MS analysis was carried out using standard techniques; trypsin digestion of protein and analysis using a 4000Q-Trap mass spectrometer (Applied Biosystems, Warrington, UK). Fragment ion spectra were searched using the Mascot search tool (Matrix Science Ltd., London, UK) against a weekly updated copy of the Uniprot protein database (see http://www.uniprot.org). Peptides with probability-based Mowse scores exceeding a threshold (p < 0.05), and thus indicating a significant or extensive homology, were considered to be acceptable matches. Three peptides exceeding p < 0.05 were required for a protein to be considered as a 'hit'.
Statistics
Significance was calculated using analysis of variance unless otherwise stated. Non-linear regression to calculate the K d was done using the programme Prism. Figure 1A shows a major labelled band, competed out by unlabelled PR, was seen at 68,600 + 1503 kDa (mean + SEM, n=5 separate runs). A minor band was seen at around 150,000 kDa in some experiments.
Results
SDS polyacrylamide gel electrophoresis of labelled HUVEC proteins
Binding of B-PR to endothelial cells B-PR bound to HUVECs in a time-dependent and concentration-dependent way and the binding was competed by unlabelled PR. However, 'scrambled' peptide competed equally well as the peptide with the correct amino acid sequence ( Figure 1B ). This suggested that the binding site was unspecific for the amino acid sequence of the prorenin peptide and therefore did not represent a specific receptor for that sequence. The K d was calculated as 18.7 µM and the B max as 47.2 nmol/mg HUVEC protein (non-linear regression, Prism), and this suggests a high-capacity lowaffinity binding site.
LC-MS/MS analysis of the HUVEC proteins bound to B-PR
The LC-MS/MS results gave several significant (p < 0.05) matches to human proteins. High-scoring matches that occurred in both endothelial cell extracts are shown in Table 1 . Biotinylated PR bound mainly to cytoskeletal proteins such as actin, alpha tubulin and vimentin, or to proteins which themselves are cytoskeletal-associated such as elongation factor 1 -α. Among the other proteins detected, clathrin (gi|4758012), and two receptor-like proteins (gi|16418419, Fc receptorlike and gi|4885319, g-protein receptor-like) gave significant but lower scores in one sample only. The prorenin/renin receptor 2 (PRR) was not identified as one of the proteins binding to B-PR in either cell extract. The range of molecular weights of the binding proteins identified by LC-MS/MS was somewhat lower than expected from the SDS-PAGE results, however the cell extracts run on the gels had been treated with a cross-linking reagent which may have caused some cross-linking bet-ween the proteins/peptides themselves, thus giving a higher than expected molecular weight.
Western blotting for the (pro)renin receptor
As shown in Figure 1C , endothelial cell extracts gave a single band of protein reacting with antibody to the (pro)renin receptor at a molecular weight around 80 kDa. A relatively prolonged exposure to the chemiluminescent substrate (10 minutes to overnight) was required to detect it and the positive control sample on the same blots gave bands 50, 39.5 and 28 kDa, (mean of two runs) with the major band at around 40 kDa. The higher molecular weight band of around 50 kDa appeared after longer exposure. The expected molecular weight of the 350 amino acid (pro)renin receptor is 38,887 Da, but reports in the literature give different molecular weights for the protein. The native receptor in mesangial cells was deduced to have a molecular weight of 70-80 kDa after cross-linking to renin and SDS gel electrophoresis, 14 while the cloned receptor had a molecular weight of 45 kDa, 2 which probably relates to the major band of 40 kDa in our sample. A soluble form of the receptor, 28 kDa is generated by proteolytic cleavage of the cloned receptor, 10 and this relates to the 28 kDa band seen in the positive control sample but not in the endothelial cell extract. Dimerization of the prorenin receptor occurs, 15 and our results would fit in with the molecular weight for cross-linked native receptor, because we used extracts of control cells which had been exposed to crosslinking reagent but without the addition of B-PR. The molecular weight (68.6 kDa) of the protein band labelled with B-PR was lower than that obtained with Western blotting for the (pro)renin receptor, again confirming that B-PR did not bind significantly to the receptor (Figure 1 ).
Discussion
We have used a new approach, LC-MS/MS, to look for binding sites specific for the human prorenin propart 10-20 'decoy peptide' on human endothelial cells, without pre-assumptions as to its identity compared with the (pro)renin receptor. 2 Our peptide included one more arginine (R 20 ) than the decoy peptide of Ichihara et al., 1 but this is one of the crucial arginines involved in holding the propart peptide in the active site of renin 16, 17 and its inclusion would likely enhance binding to a prorenin-activating 'receptor' rather than reducing it.
Table 1
Results from the liquid chromatography coupled with tandem mass spectrometry showing significant matches for human umbilical cord endothelial cell (HUVEC) proteins binding to the biotinylated prorenin propart peptide, and which occurred in both samples of HUVECs. The first column shows identification numbers from the Uniprot protein database (http://www. uniprot.org), and the second column gives the protein identity. The third column contains explanatory comments. B-PR1-labelled proteins which occurred in both HUVEC extracts are shown. We could not detect a specific binding site or receptor for the human prorenin propart peptide 10-20 on human endothelial cells. The initial experiments showed that binding of biotin-labelled peptide to endothelial cell proteins occurred in a concentration and time-dependent way and was competed out by unlabelled peptide. However, a scrambled peptide competed out the binding to the same extent as the native peptide, showing that binding was non-specific for amino acid sequence. Analysis using LC-MS/MS showed that the binding proteins were cytoskeletal or microtubule-associated, such as alpha tubulin, alpha-actin, vimentin and clathrin (at a lower signal level). We did not detect (pro)renin receptor protein as a binding partner for the human prorenin propart peptide. The question as to whether the peptide binds to the (pro)renin receptor is still controversial. Nabi and colleagues 18 reported that it binds to three regions of the prorenin receptor with K d of 3.5, 6.2 and 15.2 nM and that it reduces the binding of both prorenin and renin to the receptor. However, Feldt et al. 19, 20 and Batenburg and Danser 21 reported that the peptide used at micromolar concentrations failed to block prorenin signalling, suggesting that it did not bind to the (pro) renin receptor. Satofuka and colleagues 22 reported that in vitro concentrations of handle region peptide needed to suppress prorenin-stimulated ERK activation were 10-100 µmol/L, much higher than infusion levels. We added concentrations of 'decoy' peptide up to 8 × 10 -6 M to endothelial cells and this is in the region tested by others 19, 20 and also would give maximum binding based on the results of Nabi et al., 18 if it bound to the (pro)renin receptor. Our experiments were designed to look for a binding site, without making pre-assumptions as to the type of receptor. The theoretical lower limit of detection of a possible receptor, based on the (pro)renin receptor data in the literature, can be calculated: the B max reported by Nguyen et al. for binding of renin to the (pro)renin receptor is 2.8 fmol/10 5 cells, we labelled our cells at concentrations which would give B max for binding to a (pro) renin receptor, and analysed about 5 × 10 7 cells on each run of LC-MS/MS, or the equivalent of 14 pmol peptide bound, or 14 × 10 -7 binding sites per cell. In fact, we found no specific binding sites, but the human prorenin propart 10-20 peptide is taken up by endothelial cells in a non-specific way, probably by a general protein/peptide import method. Endocytosis by clathrin-coated pits 23 is one method by which macromolecules are taken up by cells. Our experiments were carried out at 4 o C with the aim of minimizing endocytosis, since the assembly of clathrin-coated pits is reduced at low temperature. Although clathrin was detected as a binding protein by LC-MS/MS the score was relatively low, and it is possible that endocytosis by coated pits did not play a major part. Other clathrin independent mechanisms of protein/peptide uptake have been described. [24] [25] [26] Cytoskeletal proteins bind directly to a number of proteins, for instance vimentin binds viral 27 and other 28 proteins , and actin binds to a large number of proteins. 29 The K d of 18 µmol/L for the prorenin propart, and a calculated B max of 47.2 nmol/mg protein, suggests that binding is high capacity with a relatively low affinity, with regard to HUVECs. By contrast the K d for angiotensin II binding to human coronary artery endothelial cells is 168 pmol/L. 30 Our results strongly suggest, first, that endothelial cells do not have a specific receptor for the human prorenin 'decoy' peptide, although they express detectable levels of protein cross-reacting with the (pro)renin receptor and, second, they take up peptides by a non-specific 'clearance' method may well to breakdown of infused peptide. Interesting physiological roles for the (pro)renin receptor have recently been reported. 15, 31 However, we found no evidence that a receptor for the prorenin 'decoy peptide' could be a therapeutic target for diabetic vascular disease.
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